Please assess the completion status of the following clinical trial:

Trial Title: Study of WST11 in Patients With Localized Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with prostate cancer and eligible for active surveillance;~* No prior treatment for prostate cancer;~* Prostate Cancer Stage up to cT2b - N0/Nx - M0/Mx (rT2c and pT2c are acceptable);~* Gleason score ≤ 3+3 For patients characterized with prostate mapping (transperineal template guided biopsy at 5mm intervals) a secondary pattern 4 is acceptable provided that it is not present in more than 3 cores from each side of the prostate and is no more than 3 mm cancer core length.~* PSA \< 10 ng/mL;~Exclusion Criteria:~* Any condition or history of illness or surgery that, in the opinion of the investigator and/or the Sponsor, might confound the results of the study or pose additional risks to the patient.~* Patients with a prior history of viral or alcoholic hepatitis, and other patients felt to be at risk for hepatotoxicity including concomitant use of potentially hepatotoxic medications or dietary supplements;~* History of non compliance with medical therapy and medical recommendations or an unwillingness or inability to complete patient self-administered questionnaires;~* Participation in a clinical study or receipt of an investigational treatment within the past 3 months;~* A history of porphyria;~* Patient with contra-indication to MRI (such as pace maker, metal prosthesis, etc.);~* All patients whose current pre-operative cardiac evaluation does not show their fitness for a procedure requiring general anesthesia;~* Patients with a history of inflammatory bowel disease or other factors which may increase the risk of fistula formation;~* Men who have received any hormonal manipulation (excluding 5-alpha reductase inhibitors) or androgen supplements within the previous 6 months;~* Men previously treated by radiation therapy (external therapy or brachytherapy) or chemotherapy or any therapy for prostate cancer;~* Men who have received or are receiving chemotherapy for prostate carcinoma or other significant cancer;~* Men who have undergone previous TURP (trans-urethral resection of the prostate);~* Men who are currently receiving any medications having potential photosensitizing effects (e.g. tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics and griseofulvin);~* Men who are receiving anticoagulant drugs (e.g.: coumadin, warfarin)~* Patient who stopped long term treatment of acetylsalicylic acid (aspirin) or other anti platelets agents less than 15 days before the procedure;~* Patient suspected of Disseminated Intravascular Coagulation (DIC) as defined by the presence of three out of the five following criteria: platelets \<LLN, PT \>ULN,aPTT \>ULN, fibrinogen\<LLN, D-Dimer \>ULN;~* A history of sun hypersensitivity or photosensitive dermatitis;~* Renal disorders (blood creatinine \> 1.5 x ULN) or known post mictional residue \> 150cc;~* Hepatic disorders (transaminases \> ULN, bilirubin \> ULN). In case of slight abnormalities, another exam should be performed. If the results are within normal ranges, then the patient can be included;~* Hematological disorders (white cells \< 2500/mm3, neutrophils \< 1500/mm3, platelets \< 140.000/mm3, Hb \< 8 g/dl);

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WST11(TOOKAD® Soluble) (Type: EXPERIMENTAL): Treatment with WST11-mediated VTP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete